Short answer
Insmed Incorporated (INSM) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $306M (up 229.6% year over year) with net income of −$164M.
Q1 2026 key financials · XBRL
- Revenue
- $306M
- +229.6% YoY
- Net income
- −$164M
- +36.3% YoY
- Operating margin
- -50.1%
- EPS (diluted)
- −$0.76
- +46.5% YoY
Source: XBRL data from the Insmed Incorporated (INSM) Q1 2026 10-Q on SEC EDGAR. USD.
Insmed Incorporated Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue, margins, segment performance, cash flow, and capital deployment figures absent from provided excerpt
- Near-term milestones: ARIKAYCE US sNDA submission anticipated in second half of 2026
- BRINSUPRI Japan regulatory decision anticipated during 2026
- Cash and securities expected to fund operations for at least next 12 months
- Headwinds: commercialization, regulatory approvals, reimbursement, manufacturing, competition, inflation, and operating losses
Risk Factors
- No material risk-factor changes disclosed versus the December 31, 2025 Form 10-K
- Business, financial condition, results, growth prospects, and stock value remain exposed to disclosed risks
- Forward-looking statements remain subject to actual results differing materially from projections
- New Rule 10b5-1 plans cover 154,121 CFO shares and 187,979 CMO shares
- Sell-to-cover arrangements create potential share sales tied to RSU and PSU vesting prices
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Insmed Incorporated quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.